• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Insiders Buying Solid Biosciences And 2 Other Stocks

    1/16/24 6:17:13 AM ET
    $AXR
    $CSBR
    $SLDB
    Homebuilding
    Real Estate
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AXR alert in real time by email

    Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Solid Biosciences

    • The Trade: Solid Biosciences Inc. (NASDAQ:SLDB) Director Joseph Edelman acquired a total of 3,410,713 shares an average price of $5.53. To acquire these shares, it cost around $18.86 million. The company’s 10% owner RA Capital Nexus Fund, L.P also bought 904,160 shares at an average price of $5.53.
    • What’s Happening: Solid Biosciences entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement.
    • What Solid Biosciences Does: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs.

    Champions Oncology

    • The Trade: Champions Oncology, Inc. (NASDAQ:CSBR) Director Daniel Mendelson acquired a total of 2,000 shares at an average price of $6.27. To acquire these shares, it cost around $12,540.
    • What’s Happening: Champions Oncology, last month, posted a loss for the second quarter.
    • What Champions Oncology Does: Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs.

    Don’t forget to check out our premarket coverage here

    AMREP

    • The Trade: AMREP Corporation (NYSE:AXR) 10% owner Rainey Lancaster bought a total of 6,800 shares at an average price of $21.93. To acquire these shares, it cost around $149,120.
    • What’s Happening: Amrep, last month, reported a decline in quarterly sales.
    • What AMREP Does: Amrep Corp through its subsidiaries is engaged in the Real estate business.

     

    Check This Out: Top 4 Tech And Telecom Stocks That May Crash In January

    Get the next $AXR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXR
    $CSBR
    $SLDB

    CompanyDatePrice TargetRatingAnalyst
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    Solid Biosciences Inc.
    $SLDB
    6/26/2025$14.00Buy
    Citigroup
    Solid Biosciences Inc.
    $SLDB
    1/8/2025$16.00Buy
    Truist
    Solid Biosciences Inc.
    $SLDB
    12/13/2024$16.00Outperform
    Wedbush
    Solid Biosciences Inc.
    $SLDB
    12/10/2024$15.00Mkt Outperform
    JMP Securities
    Champions Oncology Inc.
    $CSBR
    9/12/2024$6.00Hold → Buy
    Craig Hallum
    Solid Biosciences Inc.
    $SLDB
    7/15/2024$10.00 → $15.00Neutral → Overweight
    JP Morgan
    Solid Biosciences Inc.
    $SLDB
    6/24/2024$12.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $AXR
    $CSBR
    $SLDB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

    - IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for additional meetings with the FDA in 1H 2026 to align on a potential accelerated approval pathway for SGT-003 - - INSPIRE DUCHENNE: SGT-003 continues to be generally well tolerated with 36 participants dosed as of February 9, 2026, in Phase 1/2 trial - CHARLESTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today anno

    2/9/26 8:00:00 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:30 AM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page. About Solid BiosciencesSolid Biosciences is a precision genetic medicine company focused on advancin

    2/6/26 8:00:00 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

    - Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - Duchenne: First participant enrolled in IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled, ex-U.S. clinical trial, with dosing expected in Q1 2026 - - FA: First participant dosed in Phase 1b FALCON clinical trial; FDA Orphan Drug designation granted to SGT-212, the only dual route of administration gene therapy in development to treat Friedreich's ataxia (FA) - - CPVT: Clinical trial sites activated for ARTEMIS, a Phase 1b first-in-human clinical trial

    1/13/26 4:15:00 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXR
    $CSBR
    $SLDB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    3/13/25 4:05:03 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/21/25 5:48:02 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Perceptive Advisors Llc bought $20,150,000 worth of shares (5,000,000 units at $4.03) (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/21/25 4:17:42 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXR
    $CSBR
    $SLDB
    SEC Filings

    View All

    SEC Form 144 filed by Solid Biosciences Inc.

    144 - Solid Biosciences Inc. (0001707502) (Subject)

    2/4/26 7:44:24 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Solid Biosciences Inc.

    144 - Solid Biosciences Inc. (0001707502) (Subject)

    2/4/26 7:42:04 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Solid Biosciences Inc.

    144 - Solid Biosciences Inc. (0001707502) (Subject)

    2/2/26 8:03:55 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXR
    $CSBR
    $SLDB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Solid Biosciences with a new price target

    Needham initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

    12/4/25 8:48:04 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Solid Biosciences with a new price target

    Citigroup initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $14.00

    6/26/25 8:11:57 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Solid Biosciences with a new price target

    Truist initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

    1/8/25 8:30:04 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXR
    $CSBR
    $SLDB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Howton David T sold $121,713 worth of shares (18,894 units at $6.44), decreasing direct ownership by 16% to 97,859 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/6/26 6:05:06 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Cumbo Alexander sold $315,093 worth of shares (48,913 units at $6.44), decreasing direct ownership by 18% to 222,018 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/6/26 6:01:54 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ganot Ilan sold $46,414 worth of shares (7,205 units at $6.44) (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/6/26 6:01:49 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXR
    $CSBR
    $SLDB
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

    HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

    1/8/25 8:00:00 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Solid Biosciences Provides Third Quarter Business Update and Financial Results

    – IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash and investments; Anticipated cash runway through multiple important pipeline milestones and into 2025 – CHARLESTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update. "We are pleased with the continued advanceme

    11/8/23 4:17:49 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXR
    $CSBR
    $SLDB
    Financials

    Live finance-specific insights

    View All

    Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

    — Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants

    2/18/25 6:45:43 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

    - SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia - - Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease - - Phase 1b clinical trial initiation expected in 2H 2025 - - Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET - CHARLESTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today a

    1/7/25 4:15:00 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

    HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

    12/11/24 4:00:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXR
    $CSBR
    $SLDB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

    SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 7:59:25 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Solid Biosciences Inc.

    SC 13G - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 12:02:53 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.

    SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

    11/14/24 9:53:10 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care